MedTrace Logo

Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

NCT00330863 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 357

Last updated 2018-07-10

Study results available
· View outcomes & findings →

Summary

This study is designed to find out whether taking antipsychotic medication once every two weeks by injection compared to taking daily oral medication will help people with schizophrenia maintain better control of their symptoms.

Conditions

Interventions

DRUG

Risperidone microspheres

Minimum dose is 12.5 mg every 2 weeks. Maximum dose is 75 mg every 2 weeks.

DRUG

Risperidone

Target dose is 4 mg/day.

DRUG

Olanzapine

Target dose is 15 mg/day.

DRUG

Quetiapine

Target dose is 600 mg/day.

DRUG

Ziprasidone

Target dose is 120 mg/day.

DRUG

Aripiprazole

Target dose is 20 mg/day.

DRUG

Paliperidone

Target dose is 6 mg/day.

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Northwell Health

    lead OTHER

Principal Investigators

  • Nina R. Schooler, PhD · Steering and Implementation Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00330863 on ClinicalTrials.gov